Eli Lilly Builds $1.5 Billion Inventory Of Experimental Weight-Loss Pill As FDA Decision Looms - Eli Lilly and Co (NYSE:LLY), Novo Nordisk (NYSE:NVO)

Core Insights - Eli Lilly and Company has built up an inventory of $1.5 billion for its experimental oral weight-loss drug, orforglipron, in anticipation of an FDA decision expected in April, marking a significant increase from nearly $550 million last year [1] - The FDA has granted a fast-track review voucher for the weight-loss pill, potentially reducing the approval timeline to one or two months, compared to the usual 10 to 12 months for most new drugs [2] - Eli Lilly aims to have sufficient supply to launch the weight-loss pill across multiple countries simultaneously, pending U.S. approval [2] Financial Performance - Eli Lilly's stock has increased by 19.09% over the past year, with a recent rise of 2.27% to close at $1,038.27 [3] - Benzinga's Edge Rankings place Eli Lilly in the 90th percentile for quality and the 84th percentile for momentum, indicating strong performance relative to peers [3]